Enveda raises $311 million for AI drugs

Enveda, a biotechnology company focused on developing drugs using artificial intelligence and natural ingredients, has recently raised $311 million in a funding round. This investment values the company at $2 billion. The funds raised will be used for the further development of innovative therapies primarily aimed at treating skin conditions and maintaining weight loss after stopping GLP-1 medication.

The use of artificial intelligence in biotechnology opens new possibilities for drug discovery and development. Enveda positions itself as a leader in this field by combining existing technologies with natural, plant-based ingredients. The goal is to enhance the efficacy of new drugs while minimizing side effects. This can have a significant impact on healthcare, particularly for patients who benefit from more tailored treatment options.

Additionally, this funding round highlights the growing importance of AI in pharmacology and the broader biotech sector. Investors are increasingly confident in companies that combine technologies with traditional methods, opening the door for more investments in this segment. Enveda’s focus on closely working with natural substances raises expectations for innovative and sustainable drugs.

Enveda's current tests are focused on drugs that are effective in treating specific conditions while also supporting patients in their transition from GLP-1 medications. The results of these studies could not only change the market for AI-based drugs but also the way drugs are developed and tested in later clinical phases.

Read the full article from Techcrunch.